ABO-Incompatible Heart Transplant in Infants: A UNOS Database Review.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
08 2021
Historique:
received: 09 02 2020
revised: 15 06 2020
accepted: 17 06 2020
pubmed: 6 9 2020
medline: 7 9 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

ABO-incompatible (ABOi) heart transplantation (HT) in infants has been used to reduce waiting list time and mortality with outcomes comparable to ABO compatible (ABOc). We sought to assess trends in ABOi listing and transplantation for infants within the United Network for Organ Sharing registry and to evaluate its influence on outcomes. We reviewed infants listed for HT in the United Network for Organ Sharing registry (2007-2018). We compared demographic and clinical characteristics, waiting list duration, graft survival, and 1-year freedom from rejection between patients listed for ABOi and ABOc. Cochran-Armitage trend test, univariate nonparametric statistical methods, and Kaplan-Meier curves were used to analyze the data. During the study period, 2787 patients were listed for HT, 53% of whom were listed for ABOi. Median waiting list time for patients in blood group O receiving an ABOi transplant was significantly shorter (P < .0001). Among the 1862 patients who received HT, 15% were ABOi. The incidence of ABOi HT also increased over time. The pretransplant anti-A and anti-B titers in the ABOi group did not significantly affect outcomes. There was no difference in the incidence of rejection in the first year after transplant and no significant difference in posttransplant survival CONCLUSIONS: The number of infants listed and transplanted as ABOi has gradually increased over the past decade, with a significantly decreased waiting list time for ABOi transplants in blood group O. At 1 year after transplant, rejection was comparable between the ABOi and ABOc groups and there was no significant difference in survival.

Sections du résumé

BACKGROUND
ABO-incompatible (ABOi) heart transplantation (HT) in infants has been used to reduce waiting list time and mortality with outcomes comparable to ABO compatible (ABOc). We sought to assess trends in ABOi listing and transplantation for infants within the United Network for Organ Sharing registry and to evaluate its influence on outcomes.
METHODS
We reviewed infants listed for HT in the United Network for Organ Sharing registry (2007-2018). We compared demographic and clinical characteristics, waiting list duration, graft survival, and 1-year freedom from rejection between patients listed for ABOi and ABOc. Cochran-Armitage trend test, univariate nonparametric statistical methods, and Kaplan-Meier curves were used to analyze the data.
RESULTS
During the study period, 2787 patients were listed for HT, 53% of whom were listed for ABOi. Median waiting list time for patients in blood group O receiving an ABOi transplant was significantly shorter (P < .0001). Among the 1862 patients who received HT, 15% were ABOi. The incidence of ABOi HT also increased over time. The pretransplant anti-A and anti-B titers in the ABOi group did not significantly affect outcomes. There was no difference in the incidence of rejection in the first year after transplant and no significant difference in posttransplant survival CONCLUSIONS: The number of infants listed and transplanted as ABOi has gradually increased over the past decade, with a significantly decreased waiting list time for ABOi transplants in blood group O. At 1 year after transplant, rejection was comparable between the ABOi and ABOc groups and there was no significant difference in survival.

Identifiants

pubmed: 32888926
pii: S0003-4975(20)31422-3
doi: 10.1016/j.athoracsur.2020.06.073
pii:
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

589-594

Informations de copyright

Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Deborah Kozik (D)

Department of Cardiothoracic Surgery, University of Louisville School of Medicine and Norton Children's Hospital, Louisville, Kentucky. Electronic address: deborah.kozik@louisville.edu.

Joshua Sparks (J)

Department of Pediatrics, University of Louisville School of Medicine and Norton Children's Hospital, Louisville, Kentucky.

Jaimin Trivedi (J)

Department of Cardiothoracic Surgery, University of Louisville School of Medicine and Norton Children's Hospital, Louisville, Kentucky.

Mark S Slaughter (MS)

Department of Cardiothoracic Surgery, University of Louisville School of Medicine and Norton Children's Hospital, Louisville, Kentucky.

Erle Austin (E)

Department of Cardiothoracic Surgery, University of Louisville School of Medicine and Norton Children's Hospital, Louisville, Kentucky.

Bahaaldin Alsoufi (B)

Department of Cardiothoracic Surgery, University of Louisville School of Medicine and Norton Children's Hospital, Louisville, Kentucky.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH